Curative Biotechnology, Inc. CUBT
OTC PK
| 09/30/2025 | 03/31/2025 | 09/30/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 487.30K | 258.90K | 435.10K | ||
| Depreciation & Amortization | 21.80K | 21.90K | 21.90K | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 509.10K | 282.50K | 460.60K | ||
| Operating Income | -509.10K | -282.50K | -460.60K | ||
| Income Before Tax | -764.80K | -481.60K | -882.10K | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -764.80K | -481.60K | -882.10K | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -764.80K | -481.60K | -882.10K | ||
| EBIT | -509.10K | -282.50K | -460.60K | ||
| EBITDA | -487.00K | -260.60K | -437.60K | ||
| EPS Basic | -0.11 | -0.16 | -0.15 | ||
| Normalized Basic EPS | -0.07 | -0.05 | -0.09 | ||
| EPS Diluted | -0.11 | -0.16 | -0.15 | ||
| Normalized Diluted EPS | -0.07 | -0.05 | -0.09 | ||
| Average Basic Shares Outstanding | 6.66M | 6.21M | 6.02M | ||
| Average Diluted Shares Outstanding | 6.66M | 6.21M | 6.02M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||